MyoKardia, Inc. (NASDAQ:MYOK) released its quarterly earnings data on Monday. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.04, Bloomberg Earnings reports. MyoKardia had a negative return on equity of 16.63% and a negative net margin of 44.65%. The business had revenue of $5.60 million for the quarter, compared to analysts’ expectations of $6.73 million. During the same quarter in the prior year, the firm earned ($0.37) earnings per share. MyoKardia’s quarterly revenue was up 60.0% compared to the same quarter last year.

MyoKardia (MYOK) traded up 3.18% during midday trading on Wednesday, reaching $37.35. 2,075,820 shares of the company’s stock traded hands. MyoKardia has a 52 week low of $10.55 and a 52 week high of $37.70. The company’s 50-day moving average price is $14.29 and its 200 day moving average price is $13.21. The stock’s market capitalization is $1.17 billion.

WARNING: “MyoKardia, Inc. (NASDAQ:MYOK) Announces Quarterly Earnings Results” was first reported by Daily Political and is the property of of Daily Political. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/08/09/myokardia-inc-nasdaqmyok-announces-quarterly-earnings-results.html.

In related news, CEO Anastasios Gianakakos sold 4,300 shares of the firm’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $16.62, for a total transaction of $71,466.00. Following the transaction, the chief executive officer now owns 512,463 shares of the company’s stock, valued at $8,517,135.06. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 46.10% of the stock is currently owned by company insiders.

Institutional investors have recently modified their holdings of the stock. Highbridge Capital Management LLC acquired a new position in shares of MyoKardia during the first quarter valued at $136,000. State of Wisconsin Investment Board acquired a new position in shares of MyoKardia during the second quarter valued at $157,000. Daiwa SB Investments Ltd. acquired a new position in shares of MyoKardia during the first quarter valued at $170,000. Hershey Trust Co. raised its position in shares of MyoKardia by 116.4% in the first quarter. Hershey Trust Co. now owns 15,919 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 8,562 shares during the last quarter. Finally, Rhumbline Advisers raised its position in shares of MyoKardia by 45.4% in the second quarter. Rhumbline Advisers now owns 18,489 shares of the biotechnology company’s stock valued at $242,000 after buying an additional 5,773 shares during the last quarter. 47.74% of the stock is currently owned by hedge funds and other institutional investors.

MYOK has been the subject of several research reports. Zacks Investment Research downgraded shares of MyoKardia from a “hold” rating to a “sell” rating in a research note on Thursday, May 11th. TheStreet upgraded shares of MyoKardia from a “d+” rating to a “c” rating in a research note on Thursday, July 6th. BMO Capital Markets reiterated an “outperform” rating and set a $32.00 price objective on shares of MyoKardia in a research note on Wednesday, May 10th. Cowen and Company boosted their price objective on shares of MyoKardia from $28.00 to $56.00 in a research note on Monday. Finally, Wells Fargo & Company reiterated an “outperform” rating and set a $48.00 price objective (up from $31.00) on shares of MyoKardia in a research note on Monday. One investment analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $37.60.

About MyoKardia

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Earnings History for MyoKardia (NASDAQ:MYOK)

Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.